Roundtable discussion: Part II--Development of a pharmacoeconomic model in hypertension.
Antihypertensive medications are targeted by most health plans as a major cost center. However, the efficacy of these medications, their side effects, and their resulting ability to prevent serious long-term complications must be factored into the value equation. To illustrate the possible economic effects of a single antihypertensive agent's inclusion on a health plan's drug formulary, an innovative pharmacoeconomic model was developed. In this portion of the roundtable, the design, results, and caveats of this model are discussed.
Penna
P
P
Cox
E
E
Joseph
T
T
Lehman
L
L
Morrow
T
T
Richter
A
A
Sowers
J
J
Tepper
D
D
D000959:Antihypertensive Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D004363:Drug Utilization / Q000191:economics; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000191:economics; D017059:Models, Econometric; D010818:Practice Patterns, Physicians'; D016896:Treatment Outcome; D014481:United States
D000959:Antihypertensive Agents